A Single-Arm Exploratory Study of NatureU Hista Dissolve on Chronic Urticaria Symptoms
Key facts
- Who runs it
- OmniSolutions Laboratory Holdings Limited
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 19 people enrolled
- Started
- 4 Oct 2024
- Ended
- 1 Nov 2024
- Type of study
- Interventional
- Treatments tested
- NatureU Histra Disslove
- Record updated
- 26 October 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (15)Hide the full registry criteria
Who can take part
- Participants who signed informed consent before the study and understood the study content, procedures, and possible adverse reactions
- Adults diagnosed with chronic urticaria by a dermatologist based on clinical symptoms and medical history
- Age 18 to 65 years
- Participants with typical wheals with itching and/or angioedema symptoms of chronic urticaria and either a Urticaria Activity Score 7 of at least 7 or a Urticaria Control Test score below 12
- Participants willing to maintain normal healthy routines during the study, avoid alcohol, and avoid foods likely to trigger allergic reactions
Who cannot take part
- Participation in another clinical trial or use of prohibited drug treatment
- Severe internal organ disease, including heart disease, kidney disease, or other serious disease that could affect product metabolism
- Known allergy or intolerance to any ingredient of the study product
- Other skin disease or systemic disease that could affect urticaria manifestations
- Severe psychological disorder or cognitive impairment that could affect compliance
- Population for whom the product was contraindicated, including minors, participants planning pregnancy, pregnant or lactating participants, participants with liver or kidney disease history, and participants taking long-term medication
- Abnormal blood routine, liver function, kidney function, or other laboratory test results outside the normal range
- Heavy smoking, alcohol abuse, or other lifestyle factors that could affect study results
- Inability to follow study dietary restrictions or requirements because of religious or personal reasons
- Any other factor judged by the investigator to make participation inappropriate
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This was a single-center, open-label, single-arm, exploratory self-controlled study evaluating NatureU Histra Disslove in adults with chronic urticaria symptoms. Twenty-four participants were screened, 19 participants were enrolled, and 19 participants completed the study and were included in the effectiveness analysis. Participants took one tablet of the study product orally once daily, 20 minutes before a main meal, for 28 consecutive days. Urticaria Control Test, Urticaria Activity Score 7, and Dermatology Life Quality Index assessments were performed at baseline, Day 14, and Day 28. Safety was monitored during the study.
The group in the trial
- NatureU Histra DissloveTreatment being tested
Participants received NatureU Histra Disslove, one tablet orally once daily 20 minutes before a main meal for 28 consecutive days.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Single-Center, Open-Label, Single-Arm Exploratory Self-Controlled Study of NatureU Histra Disslove on Urticaria Control, Urticaria Activity, and Dermatology Quality of Life in Adults With Chronic Urticaria Symptoms
- Record updated
- 26 October 2026